News
SCLX
0.7640
-7.97%
-0.0662
Weekly Report: what happened at SCLX last week (0429-0503)?
Weekly Report · 4d ago
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Scilex Holding Price Target Cut to $8.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Scilex Holding, Lowers Price Target to $8
Benzinga · 6d ago
Maintaining Buy Rating on Scilex: Strategic and Financial Optimism Despite Challenges
TipRanks · 05/03 10:39
SCILEX HOLDING COMPANY <SCLX.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $8 FROM $12
Reuters · 05/03 10:17
Weekly Report: what happened at SCLX last week (0422-0426)?
Weekly Report · 04/29 10:40
Scilex Holding Co: Current report
Press release · 04/27 06:18
SCILEX HOLDING COMPANY ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING
Reuters · 04/25 20:01
Scilex falls on direct offering to raise $15M
Scilex stock fell 3.8% in pre-market trade. The company is looking to raise $15M through a direct offering of 15M shares of its common stock and warrants. Scilex falls on direct offering to raise £1.5M.
Seeking Alpha · 04/24 12:14
SCILEX HOLDING COMPANY ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
Reuters · 04/24 12:00
Press Release: Scilex Holding Company Announces $15 Million Registered Direct Offering
Scilex Holding Company Announces $15 million Registered Direct Offering. Scilex is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company has entered into a definitive agreement with certain institutional investors for the purchase and sale of 15,000,000 shares of its common stock. The closing of the offering is expected to occur in April 2024.
Dow Jones · 04/24 12:00
Weekly Report: what happened at SCLX last week (0415-0419)?
Weekly Report · 04/22 10:33
Scilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattack
Healthcare Scilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattack. Company plans to focus on late-stage pipeline programs such as SP-102. ZTlido preliminary sales for Q1, 2024 show growth in the range of 24-38%.
Seeking Alpha · 04/16 13:14
Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company estimates ZTlido's gross and net sales for the quarter ended March 31, 2024. Scilex plans to reduce research and development and other expenses in 2024.
Benzinga · 04/16 13:08
SCILEX HOLDING CO - PLANS TO REDUCE R&D AND OTHER ADMINISTRATIVE EXPENSES AND TO FOCUS ON ITS LATE-STAGE PIPELINE PROGRAMS SUCH AS SP-102
Reuters · 04/16 13:04
Press Release: Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido(R) for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company provides preliminary unaudited financial results for gross and net sales for ZTlido(R) for the first quarter of 2024. The Company plans to reduce research and development and other administrative expenses in 2024. Scilex is an innovative company focused on non-opioid pain management products for the treatment of acute and chronic pain.
Dow Jones · 04/16 13:00
Weekly Report: what happened at SCLX last week (0408-0412)?
Weekly Report · 04/15 10:26
Scilex Holding Launches Co-Pay Programs For ZTlido And ELYXYB For Commercially Insured Patients And Addition Of ELYXYB To Multi-State Medicaid Pharmaceutical Purchasing Group To Purchasing Pool
Benzinga · 04/09 13:10
SCILEX HOLDING CO: ON APRIL 1, A MULTI-STATE MEDICAID PHARMACEUTICAL PURCHASING GROUP ADDED ELYXYB TO ITS PURCHASING POOL
Reuters · 04/09 13:05
More
Webull provides a variety of real-time SCLX stock news. You can receive the latest news about Scilex Holding Co through multiple platforms. This information may help you make smarter investment decisions.
About SCLX
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.